Drug Pricing Investigation By Department Of Justice Requested - Rep. Coburn
Executive Summary
The pharmaceutical industry's pricing practices for chemically similar brand name drugs merits federal investigation, Rep. Coburn (R-Okla.) said in a June 15 letter to U.S. Attorney General Reno.
You may also be interested in...
Rx Price Clusters Parallel Managed Care Premiums, AstraZeneca Exec Says
Deeply discounted launch prices for brand name pharmaceuticals are rare because promotional costs are high regardless of price, AstraZeneca Director of Public Policy Robert Freeman, PhD, suggested during the HHS conference on drug pricing Aug. 8 in Washington, D.C.
Rx Price Clusters Parallel Managed Care Premiums, AstraZeneca Exec Says
Deeply discounted launch prices for brand name pharmaceuticals are rare because promotional costs are high regardless of price, AstraZeneca Director of Public Policy Robert Freeman, PhD, suggested during the HHS conference on drug pricing Aug. 8 in Washington, D.C.
Jeffords Rx Re-Importation Bill Gains Sen. Gorton's Support
Sen. Jeffords' (R-Vt.) prescription drug re-importation bill has gained the support of another border-state Republican: Sen. Gorton of Washington.